Analysis of The Budget Impact of Secukinumab use Versus Anti-Tnf Agents in Ankylosing Spondylitis Patients

OBJECTIVES: To conduct an analysis of the budget impact of secukinumab use in the treatment of Ankylosing Spondylitis in Colombia versus TNF-α inhibitors. METHODS: A budget impact model was developed to compare the drug acquisition and administration costs with and without the introduction of secukinumab to the Health Benefit Plan for treatment of Ankylosing Spondylitis patients. This analysis was developed from the adaptation of a cost-effectiveness analysis that mimics the natural history of the disease via a Markov model. TNF-α inhibitors currently available in Colombia were included in the analysis. The licensed posology was used for all treatments. Current and future market share projections were obtained from SISMED and a marketing study. The impact of secukinumab use was estimated for the first, second, and third year. RESULTS: Total cumulative budget impact in Colombian Pesos (COP$) when including secukinumab in the benefits plan for treatment of Ankylosing Spondylitis patients generates savings of COP$ 46,957,425,832, which corresponds to a value of COP$ 952.65 per capita at third year and represents savings of 0.128% on 2017 Capitation Payment Unit (UPC). CONCLUSIONS: Secukinumab is a cost-saving treatment option for Ankylosing Spondylitis from the first year for the Colombian healthcare system. This is a result of comparing impact of secukinumab inclusion for treatment of Ankylosing Spondylitis patients versus current setting of TNF-α inhibitors therapy.